A Recombinant Live Oral Cholera Vaccine

Production of antitoxic immunity by live oral cholera vaccine.

Present knowledge about the extent of antitoxic immunity produced by cholera vaccination is meagre. Kasai and Burrows (J. Infect. Diseases 116:606, 1966) reported that the parenteral injection of killed vaccine increases the antitoxin titer of rabbit sera. They also showed that patients recovering from cholera develop antitoxic activity in their sera. Bhattacharya and Mukerjee (unpublished data...

Stockpiling oral cholera vaccine.

Editorials 714 Cholera is re-emerging as a threat on the global public health stage. The number of reported cases worldwide is back at the peak level observed two decades ago, 1 new Vibrio cholerae strains have appeared and antimicrobial resistance has increased. Weak surveillance systems and the possibility of travel and trade sanctions contribute to widespread underreporting of cholera cases,...

Live recombinant Salmonella oral vaccine against avian influenza viruses.

In 1997, the avian influenza virus (AIV) subtype H5N1 was first reported to infect humans.1 Up to 3 March 2015, the cumulative number of confirmed human cases of H5N1 was 784, with 429 deaths. There is no evidence that H5N1 viruses can transmit efficiently from person to person.2 Therefore, the key to prevention of a human H5N1 pandemic is to first control the H5N1 virus in birds. Traditionally...

Safety and Immunogenicity of a Live Oral Recombinant Cholera Vaccine VA1.4: A Randomized, Placebo Controlled Trial in Healthy Adults in a Cholera Endemic Area in Kolkata, India

BACKGROUND A live oral cholera vaccine VA 1.4 developed from a non-toxigenic Vibrio cholerae O1 El Tor strain using ctxB gene insertion was further developed into a clinical product following cGMP and was evaluated in a double-blind randomized placebo controlled parallel group two arm trial with allocation ratio of 1∶1 for safety and immunogenicity in men and women aged 18-60 years from Kolkata...

Modified Live Virus Hog Cholera Vaccine--M.L.V